MCID: PNL012
MIFTS: 57

Penile Cancer

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Penile Cancer

MalaCards integrated aliases for Penile Cancer:

Name: Penile Cancer 12 20 36 15
Penile Carcinoma 12 20 17
Penis Carcinoma 12 15 70
Malignant Neoplasm of Penis 70 32
Penile Neoplasms 44 70
Penile Neoplasm 12 17
Malignant Neoplasm of Body of Penis 12
Malignant Penile Tumor 12
Carcinoma of the Penis 20
Carcinoma of Penis 12
Penis Cancer 20
Penile Ca 12
Ca Penis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11615 DOID:3449
KEGG 36 H00025
ICD9CM 34 187.3 187.4
MeSH 44 D010412
NCIt 50 C7547 C9061
ICD10 32 C60 C60.2 C60.9
UMLS 70 C0030849 C0153600 C0153601 more

Summaries for Penile Cancer

KEGG : 36 Penile cancer is a disease with a high morbidity and mortality. Its prevalence is relatively rare in developed countries but more common in South America and East Africa. Squamous cell carcinoma (SCC) is the predominant tumor type in penile cancer, accounting for 95% of cases. Penile cancers are thought to arise from the progression of precursor lesions and can be subdivided into human papilloma virus (HPV) positive and HPV negative cases. Most common disrupted pathways, both in HPV-mediated and HPV-independent penile carcinogenesis, involve the p14ARF/MDM2/p53 and/or p16INK4a/cyclin D/Rb pathways. HPVs exert their oncogenic effect by expressing the oncoproteins E6 and E7, which bind to and inactivate the p53 and Rb tumor suppressor gene products, respectively. HPV independent mechanisms of pathway inactivation include silencing of the p16INK4a gene by promoter hypermethylation, somatic mutations of the p53 gene, over-expression of MDM2 and mutation of p14ARF. Several other molecular events include alterations in the activity and/or expression of ras and myc genes, cyclo-oxygenase-2 (COX) pathway and prostaglandin E2 synthase. These alterations have been described in both HPV-positive and -negative penile cancers.

MalaCards based summary : Penile Cancer, also known as penile carcinoma, is related to human papillomavirus infectious disease and squamous cell papilloma. An important gene associated with Penile Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Viral carcinogenesis and Toll-like Receptor Signaling Pathway. The drugs Ifosfamide and Isophosphamide mustard have been mentioned in the context of this disorder. Affiliated tissues include lymph node, skin and prostate, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Penile cancer is cancer that develops in the skin or tissues of the penis. Symptoms may include abnormal... more...

Related Diseases for Penile Cancer

Diseases related to Penile Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 507)
# Related Disease Score Top Affiliating Genes
1 human papillomavirus infectious disease 32.1 TP53 TERT CDKN2A
2 squamous cell papilloma 31.1 TP53 HRAS GP5 CDKN2A
3 papillary squamous carcinoma 30.7 EGFR CDKN2A
4 verrucous carcinoma 30.6 TP53 PTEN EGFR CDKN2A CCND1
5 papilloma 30.6 TP53 RB1 PTEN KRAS EGFR CDKN2A
6 vulvar intraepithelial neoplasia 30.5 TP53 CDKN2A
7 anogenital venereal wart 30.5 TP53 RB1 GP5 CDKN2A
8 basaloid squamous cell carcinoma 30.4 TP53 EGFR CDKN2A
9 bowenoid papulosis 30.4 TERT CDKN2A CCND1
10 mucoepidermoid carcinoma 30.2 TP53 EGFR CDKN2A CCND1
11 testicular cancer 30.2 TP53 TERT PTEN KRAS EGFR
12 suppressor of tumorigenicity 3 30.1 TP53 RB1 CDKN2A
13 skin squamous cell carcinoma 30.1 TP53 HRAS CDKN2A
14 merkel cell carcinoma 30.1 TP53 RB1 CDKN2A CD274
15 keratosis 30.1 TP53 PIK3CA HRAS CDKN2A
16 cervix carcinoma 30.0 TP53 PIK3CA GP5 EGFR CDKN2A
17 in situ carcinoma 30.0 TP53 PTEN PIK3CA PDPN HRAS EGFR
18 exanthem 30.0 KRAS HRAS EGFR CRP CD274
19 transitional cell carcinoma 30.0 TP53 PTEN HRAS EGFR CDKN2A
20 breast adenocarcinoma 30.0 TP53 RB1 PIK3CA KRAS EGFR
21 keratinizing squamous cell carcinoma 29.9 TP53 EGFR CNDP2 CDKN2A
22 gastric adenocarcinoma 29.9 TP53 PTEN PIK3CA KRAS HRAS CDKN2A
23 vulva squamous cell carcinoma 29.9 TP53 PIK3CA GP5 EGFR CDKN2A CD274
24 cervix uteri carcinoma in situ 29.8 TP53 RB1 GP5 CDKN2A
25 cervical squamous cell carcinoma 29.7 TP53 PIK3CA KRAS EGFR CDKN2A CCND1
26 lymphoma 29.7 TP53 RB1 PIK3CA EGFR CDKN2A CD274
27 angiosarcoma 29.7 TP53 PDPN KRAS
28 colon adenocarcinoma 29.7 TP53 PTEN PIK3CA KRAS EGFR CD274
29 squamous cell carcinoma 29.7 TP53 RB1 PTEN PIK3CA PDPN HRAS
30 carcinosarcoma 29.7 TP53 PTEN PIK3CA KRAS HRAS EGFR
31 basal cell carcinoma 29.7 TP53 TERT PTEN EGFR CDKN2A CD274
32 penile benign neoplasm 29.6 TP53 PIK3CA PDPN HOXA3 GP5 CNDP2
33 adenosquamous carcinoma 29.5 TP53 PTEN PIK3CA KRAS EGFR CDKN2A
34 penile disease 29.5 TP53 RB1 PTEN GP5 EGFR CDKN2A
35 renal cell carcinoma, nonpapillary 29.4 TP53 PTEN PIK3CA MIR509-1 HRAS EGFR
36 cervical cancer 29.4 TP53 TERT RB1 PTEN PIK3CA HRAS
37 oropharynx cancer 29.3 TP53 PIK3CA HRAS GP5 EGFR CDKN2A
38 lymphangioma 29.3 TP53 PIK3CA PDPN KRAS HRAS EGFR
39 squamous cell carcinoma, head and neck 29.3 TP53 RB1 PTEN PIK3CA HRAS EGFR
40 thrombocytopenia 29.2 TERT PTEN KRAS GP5 CRP CD274
41 peripheral nervous system disease 29.1 TP53 SCN10A PTEN HRAS EGFR CRP
42 vulva cancer 29.1 TP53 PTEN PIK3CA MIR223 HRAS GP5
43 adenocarcinoma 29.1 TP53 RB1 PTEN PIK3CA KRAS HRAS
44 glioblastoma 29.1 TP53 TERT RB1 PTEN PIK3CA HRAS
45 melanoma 29.1 TP53 TERT RB1 PTEN PIK3CA KRAS
46 bladder cancer 28.3 TP53 TERT RB1 PTEN PIK3CA MIR223
47 gastric cancer 28.1 TP53 TERT RB1 PTEN PIK3CA MIR223
48 malignant tumor of penis 11.5
49 penis carcinoma in situ 11.2
50 penis sarcoma 11.2

Graphical network of the top 20 diseases related to Penile Cancer:



Diseases related to Penile Cancer

Symptoms & Phenotypes for Penile Cancer

GenomeRNAi Phenotypes related to Penile Cancer according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.01 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.01 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.01 KRAS
4 Decreased viability GR00106-A-0 10.01 KRAS
5 Decreased viability GR00221-A-1 10.01 CDKN2A EGFR HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.01 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.01 CDKN2A HRAS
8 Decreased viability GR00221-A-4 10.01 CDKN2A EGFR PIK3CA
9 Decreased viability GR00301-A 10.01 KRAS
10 Decreased viability GR00381-A-1 10.01 KRAS
11 Decreased viability GR00402-S-2 10.01 PIK3CA

MGI Mouse Phenotypes related to Penile Cancer:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 CCND1 CD82 CDKN2A CNDP2 CRP EGFR
2 homeostasis/metabolism MP:0005376 10.44 CCND1 CD274 CD82 CDKN2A CRP EGFR
3 growth/size/body region MP:0005378 10.37 CCND1 CDKN2A CNDP2 EGFR HOXA3 HRAS
4 immune system MP:0005387 10.37 CCND1 CD274 CDKN2A CNDP2 CRP EGFR
5 cellular MP:0005384 10.36 CCND1 CD274 CD82 CDKN2A EGFR HOXA3
6 endocrine/exocrine gland MP:0005379 10.35 CCND1 CDKN2A CNDP2 EGFR HOXA3 HRAS
7 hematopoietic system MP:0005397 10.33 CCND1 CD274 CDKN2A CNDP2 EGFR HOXA3
8 digestive/alimentary MP:0005381 10.32 CCND1 CDKN2A EGFR HOXA3 HRAS KRAS
9 integument MP:0010771 10.32 CCND1 CD274 CDKN2A CNDP2 EGFR HRAS
10 nervous system MP:0003631 10.21 CCND1 CDKN2A EGFR HOXA3 HRAS KRAS
11 neoplasm MP:0002006 10.2 CCND1 CD82 CDKN2A EGFR HRAS KRAS
12 muscle MP:0005369 10.18 CDKN2A EGFR HOXA3 HRAS KRAS PDPN
13 liver/biliary system MP:0005370 10.1 CDKN2A CNDP2 EGFR KRAS PTEN RB1
14 no phenotypic analysis MP:0003012 10.06 CD274 CDKN2A EGFR HRAS KRAS PIK3CA
15 normal MP:0002873 10.02 CCND1 EGFR GP5 HRAS KRAS PTEN
16 respiratory system MP:0005388 9.97 CCND1 CDKN2A CNDP2 EGFR HOXA3 HRAS
17 reproductive system MP:0005389 9.96 CCND1 CDKN2A CNDP2 EGFR KRAS PIK3CA
18 pigmentation MP:0001186 9.8 CDKN2A EGFR KRAS PTEN RB1 TP53
19 skeleton MP:0005390 9.77 CCND1 CD274 CDKN2A EGFR HOXA3 HRAS
20 vision/eye MP:0005391 9.32 CCND1 CD82 CDKN2A CNDP2 EGFR KRAS

Drugs & Therapeutics for Penile Cancer

Drugs for Penile Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Isophosphamide mustard Phase 3 100427
3 Alkylating Agents Phase 3
4
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
5
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
6
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
7
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
8
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
9
Fluorouracil Approved Phase 2 51-21-8 3385
10
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
11
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
12
Ipilimumab Approved Phase 2 477202-00-9
13
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
14
Durvalumab Approved, Investigational Phase 2 1428935-60-7
15
nivolumab Approved Phase 2 946414-94-4
16
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
17
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
18
Pembrolizumab Approved Phase 2 1374853-91-4
19
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
20
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
21
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3
22 topoisomerase I inhibitors Phase 2
23 Anti-Infective Agents Phase 2
24 Dermatologic Agents Phase 2
25 Antiviral Agents Phase 2
26 interferons Phase 2
27 Interferon-alpha Phase 2
28 Immunosuppressive Agents Phase 2
29 Antirheumatic Agents Phase 1, Phase 2
30 Anti-Retroviral Agents Phase 1, Phase 2
31 Anti-HIV Agents Phase 1, Phase 2
32 Immunologic Factors Phase 2
33 Adjuvants, Immunologic Phase 2
34 Antibodies Phase 2
35 Immunoglobulins Phase 2
36 Antibodies, Monoclonal Phase 2
37 Immunoglobulins, Intravenous Phase 2
38 Histone Deacetylase Inhibitors Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Immunoglobulin G Phase 2
41 Interleukin-12 Phase 2
42 Vaccines Phase 1, Phase 2
43 Albumin-Bound Paclitaxel Phase 2
44 Antimitotic Agents Phase 2
45 Tubulin Modulators Phase 2
46
Gemcitabine Approved Phase 1 95058-81-4 60750
47 Freund's Adjuvant Phase 1
48 Antimetabolites Phase 1
49
Gabapentin Approved, Investigational 60142-96-3 3446
50
Sodium citrate Approved, Investigational 68-04-2

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Recruiting NCT02305654 Phase 3 Paclitaxel;Ifosfamide;Cisplatin
2 Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis. Unknown status NCT01728233 Phase 2 Dacomitinib
3 AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males Completed NCT01209325 Phase 2
4 A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis Completed NCT03114254 Phase 2 Cabazitaxel
5 A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis Completed NCT02057913 Phase 2 Vinflunine
6 A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis Completed NCT00512096 Phase 2 Ifosfamide;Paclitaxel (Taxol);Cisplatin
7 Phase II Study of Irinotecan (CPT 11) and Cisplatin (CDDP) in Metastatic or Locally Advanced Penile Carcinoma Completed NCT00066391 Phase 2 cisplatin;irinotecan hydrochloride
8 ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS Completed NCT00002506 Phase 2 isotretinoin
9 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
10 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
11 Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP Recruiting NCT02817958 Phase 2 Chemotherapy TIP
12 Activity and Tolerability of Maintenance Avelumab Immunotherapy After First Line Polychemotherapy Including Platinum in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Recruiting NCT03774901 Phase 2 Avelumab
13 A Phase II Trial of Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer: LACOG 0218 HERCULES Trial Recruiting NCT04224740 Phase 2 Pembrolizumab;Standard of care therapy
14 PERICLES (PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study)-a Phase 2 Study of Atezolizumab With or Without Radiotherapy in Penile Cancer Recruiting NCT03686332 Phase 2 Arm A: Atezolizumab and Radiotherapy;Arm B: Atezolizumab
15 A Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma. Recruiting NCT04231981 Phase 2 INCMGA0012
16 A Single Center and Single Arm Study of TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer Recruiting NCT04475016 Phase 2 Albumin-Bound Paclitaxel;Ifosfamide;Cisplatin;Nimotuzumab;Triprilimab
17 A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy Recruiting NCT03391479 Phase 2 Avelumab
18 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
19 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
20 Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma Recruiting NCT04357873 Phase 2 pembrolizumab; vorinostat
21 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
22 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
23 Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Active, not recruiting NCT03012581 Phase 2 Nivolumab
24 Phase II Trial of M7824 in Subjects With HPV Associated Malignancies Active, not recruiting NCT03427411 Phase 2 M7824
25 Therapeutic HPV Vaccine Trial +/- Anti-CD40 in HPV-driven Squamous Cell Carcinoma Suspended NCT03418480 Phase 1, Phase 2 HPV vaccine
26 Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy Terminated NCT02837042 Phase 2 Pembrolizumab
27 Phase II Study Of Weekly Docetaxel In Patients With Advanced Epidermoid Carcinoma Of The Penis Terminated NCT00058448 Phase 2 docetaxel
28 Phase II Study With Pazopanib and Weekly Paclitaxel in Metastatic or Locally Advanced Squamous Penile Carcinoma Patients Previously Treated With Cisplatin Based Chemotherapy Terminated NCT02279576 Phase 2 Pazopanib;Paclitaxel
29 A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma Withdrawn NCT02014831 Phase 2 Cetuximab;TIP
30 Pilot Study on Concurrent Cisplatin-based Chemotherapy Combined With Vaccination Therapy With the P16_37-63 Peptide in Patients With HPV- and p16INK4a-positive Cancer Completed NCT02526316 Phase 1
31 VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER Completed NCT00019110 Phase 1
32 A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1 DCC-2618;DCC-2618
33 A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
34 A Phase I Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma Not yet recruiting NCT04491942 Phase 1 Cisplatin;Elimusertib;Gemcitabine Hydrochloride
35 Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] Unknown status NCT02104063
36 Risk of Cancer in Patients Exposed to Gabapentin in the GPRD Completed NCT01236053 Gabapentin prescriptions
37 Videoscopic Versus Open Inguinal Lymphadenectomy for Sentinel Node Positive Cutaneous Malignancies and Genitourinary Staging Procedures Completed NCT01526486
38 A Randomized Trial of Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00955929 Placebo QHS and sildenafil and questionnaires;Sildenafil and questionnaire;Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
39 Monocentric Study of Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas From a Biological Specimen. Completed NCT02981862
40 Integrating a Health Information Technology System With a Web-based Mobile Health Educational Intervention to Support More Effective Provider-patient Communication and HPV Vaccine Utilization Completed NCT03346915
41 Development of Diagnostics and Treatment of Urological Cancers Recruiting NCT02994758
42 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
43 A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination Not yet recruiting NCT03856437
44 The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Not yet recruiting NCT04028479 Systemic Treatment (T)
45 INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue Suspended NCT04574427

Search NIH Clinical Center for Penile Cancer

Cochrane evidence based reviews: penile neoplasms

Genetic Tests for Penile Cancer

Anatomical Context for Penile Cancer

MalaCards organs/tissues related to Penile Cancer:

40
Lymph Node, Skin, Prostate, Tongue, Testis, Neutrophil, Bone

Publications for Penile Cancer

Articles related to Penile Cancer:

(show top 50) (show all 1693)
# Title Authors PMID Year
1
Erectile function after partial penectomy for penile cancer. 61
33620995 2021
2
Editorial Comment: Erectile function after partial penectomy for penile cancer. 61
33620996 2021
3
Salvage therapy for localized recurrences of penile cancer. 61
33742976 2021
4
A Lack of Palliative Therapy Use in Patients With Advanced Penile Cancer. 61
32752928 2021
5
[Palliative needs of advanced penile cancer in a nonagenarian patient]. 61
33441240 2021
6
High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis. 61
33537466 2021
7
Lessons learned from histological step-sectioning of sentinel lymph nodes in penile cancer. 61
32979281 2021
8
Re: Paolo Dell'Oglio, Hielke M. de Vries, Elio Mazzone, et al. Hybrid Indocyanine Green-99mTc-nanocolloid for Single-photon Emission Computed Tomography and Combined Radio- and Fluorescence-guided Sentinel Node Biopsy in Penile Cancer: Results of 740 Inguinal Basins Assessed at a Single Institution. Eur Urol 2020;78:865-72. 61
33402294 2021
9
[Penile Cancer: A case for non-lymph node disease following a negative sentinel node exploration.] 61
33650543 2021
10
Editorial Comment to Human papilloma virus prevalence in penile cancer: A multicenter study from Denmark (DaPeCa-6). 61
33745211 2021
11
Management of Advanced Penile Cancer. 61
33308870 2021
12
Surgical outcomes of glansectomy and split thickness skin graft reconstruction for localized penile cancer. 61
33811978 2021
13
Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study. 61
33789689 2021
14
Reply to Christian Daniel Fankhauser, Arie Parnham, Vijay Sangar's Letter to the Editor re: Paolo Dell'Oglio, Hielke M. de Vries, Elio Mazzone, et al. Hybrid Indocyanine Green-99mTc-nanocolloid for Single-photon Emission Computed Tomography and Combined Radio- and Fluorescence-guided Sentinel Node Biopsy in Penile Cancer: Results of 740 Inguinal Basins Assessed at a Single Institution. Eur Urol 2020;78:865-72. 61
33436166 2021
15
Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed? 61
33678229 2021
16
Current practice patterns of society of urologic oncology members in performing inguinal lymph node staging/therapy for penile cancer: A survey study. 61
33775532 2021
17
Management of penile cancer patients during the COVID-19 pandemic: An eUROGEN accelerated Delphi consensus study. 61
33397593 2021
18
Methodology for triage of urologic surgical cases in the setting of a pandemic. 61
33676485 2021
19
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. 61
33770291 2021
20
Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. 61
33270909 2021
21
F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma. 61
33685842 2021
22
[Cancers of the external genital organs of male in Hérault: Results from the Hérault tumor register (RTH) over a period of 30 years (1987-2016)]. 61
33593695 2021
23
Oncologic outcomes and subsequent treatment following organ sparing surgery for penile carcinoma: The University of Texas M.D. Anderson Cancer Center Experience. 61
33612354 2021
24
Urethral cancer managed with phallus preserving surgery: a case report. 61
33608031 2021
25
A population-level analysis of nonsquamous penile cancer: The importance of histology. 61
33257222 2021
26
Lichen Sclerosus and Phimosis - Discrepancies Between Clinical and Pathological Diagnosis and Its Consequences. 61
33248142 2021
27
DaPeCa-8: drawing the map of lymphatic drainage in patients with invasive penile cancer - evidence from SPECT/CT and sentinel node surgery. 61
33569972 2021
28
[Quality of care criteria in the treatment of penile cancer]. 61
33452551 2021
29
Penile cancer. 61
33574296 2021
30
Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis? 61
33668548 2021
31
A novel predictive model for pelvic lymph node metastasis in patients with penile cancer: A multi-institutional study. 61
33622619 2021
32
Prognostic Factors in Penile Cancer: Should We Avoid Inguinal Lymph Node Staging? 61
33601381 2021
33
Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. 61
33636562 2021
34
Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men With Clinically Node-negative (cN0) Penile Cancer. 61
33636210 2021
35
The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils. 61
33273057 2021
36
Final results of the PräVAC trial: prevention of wound complications following inguinal lymph node dissection in patients with penile cancer using epidermal vacuum-assisted wound closure. 61
32372159 2021
37
Penile preserving surgery in penile cancer management. 61
33733263 2021
38
DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer. 61
33448605 2021
39
Adjuvant radiotherapy for node-positive penile cancer. 61
33462422 2021
40
DaPeCa-9 - cohabitation and socio-economic conditions predict penile cancer-specific survival in a national clinical study from Denmark. 61
33554693 2021
41
Penile cancer. 61
33574340 2021
42
Re: Falcone et al.: Total Glans Resurfacing for the Management of Superficial Penile Cancer: A Retrospective Cohort Analysis in a Tertiary Referral Center (Urology 2020;145:281-286). 61
33359491 2021
43
Update on organ preserving surgical strategies for penile cancer. 61
33610446 2021
44
Phallus Preservation in Penile Cancer Surgery: Patient-reported Aesthetic & Functional Outcomes. 61
33600836 2021
45
Optimal treatment for penile verrucous carcinoma: a systematic literature review. 61
33514369 2021
46
Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. 61
32380900 2021
47
Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. 61
33650835 2021
48
Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer. 61
33314806 2021
49
Serum CXCL5 level is associated with tumor progression in penile cancer. 61
33458757 2021
50
Oncological therapy to Swedish men with metastatic penile cancer 2000-2015. 61
33030399 2021

Variations for Penile Cancer

Cosmic variations for Penile Cancer:

9 (show all 30)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM107894721 TP63 skin,penis,carcinoma,NS c.1910C>T p.A637V 3:189894381-189894381 3
2 COSM113474690 TP63 skin,penis,carcinoma,NS c.1385C>T p.A462V 3:189894381-189894381 3
3 COSM88644633 TP63 skin,penis,carcinoma,NS c.1922C>T p.A641V 3:189894381-189894381 3
4 COSM114684035 TP63 skin,penis,carcinoma,NS c.1628C>T p.A543V 3:189894381-189894381 3
5 COSM89453262 TP63 skin,penis,carcinoma,NS c.1640C>T p.A547V 3:189894381-189894381 3
6 COSM90478215 TP63 skin,penis,carcinoma,NS c.*150C>T p.? 3:189894381-189894381 3
7 COSM144013113 TP53 skin,penis,carcinoma,NS c.491G>A p.R164H 17:7675088-7675088 3
8 COSM143943565 TP53 skin,penis,carcinoma,NS c.47G>A p.R16H 17:7675088-7675088 3
9 COSM143370595 TP53 skin,penis,carcinoma,NS c.407G>A p.R136H 17:7675088-7675088 3
10 COSM144309944 TP53 skin,penis,carcinoma,NS c.407G>A p.R136H 17:7675088-7675088 3
11 COSM142559914 TP53 skin,penis,carcinoma,NS c.407G>A p.R136H 17:7675088-7675088 3
12 COSM105619860 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
13 COSM122733880 TP53 skin,penis,carcinoma,NS c.128G>A p.R43H 17:7675088-7675088 3
14 COSM121875575 TP53 skin,penis,carcinoma,NS c.128G>A p.R43H 17:7675088-7675088 3
15 COSM142837093 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
16 COSM122271291 TP53 skin,penis,carcinoma,NS c.128G>A p.R43H 17:7675088-7675088 3
17 COSM106052917 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
18 COSM144086975 TP53 skin,penis,carcinoma,NS c.47G>A p.R16H 17:7675088-7675088 3
19 COSM143156608 TP53 skin,penis,carcinoma,NS c.47G>A p.R16H 17:7675088-7675088 3
20 COSM112253124 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
21 COSM87897745 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
22 COSM111758247 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
23 COSM144650780 TP53 skin,penis,carcinoma,NS c.407G>A p.R136H 17:7675088-7675088 3
24 COSM145017326 TP53 skin,penis,carcinoma,NS c.407G>A p.R136H 17:7675088-7675088 3
25 COSM93183307 TP53 skin,penis,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 3
26 COSM87133066 PIK3CA skin,penis,carcinoma,NS c.317G>T p.G106V 3:179199142-179199142 3
27 COSM148933429 PIK3CA skin,penis,carcinoma,NS c.317G>T p.G106V 3:179199142-179199142 3
28 COSM89197987 MYCN skin,penis,carcinoma,NS c.131C>T p.P44L 2:15942195-15942195 3
29 COSM147761607 MYCN skin,penis,carcinoma,NS c.157+1452C>T p.? 2:15942195-15942195 3
30 COSM103913221 DOT1L skin,penis,carcinoma,NS c.4292C>T p.A1431V 19:2226813-2226813 3

Expression for Penile Cancer

Search GEO for disease gene expression data for Penile Cancer.

Pathways for Penile Cancer

Pathways related to Penile Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

Pathways related to Penile Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 TP53 RB1 PIK3CA KRAS HRAS EGFR
2
Show member pathways
13.14 TP53 RB1 PTEN PIK3CA KRAS HRAS
3
Show member pathways
13.04 TP53 TERT RB1 PTEN PIK3CA KRAS
4
Show member pathways
13.02 TP53 RB1 PIK3CA KRAS HRAS EGFR
5
Show member pathways
12.98 RB1 PTEN PIK3CA KRAS HRAS EGFR
6
Show member pathways
12.97 RB1 KRAS HRAS EGFR CDKN2A CCND1
7
Show member pathways
12.91 TP53 RB1 PTEN PIK3CA KRAS HRAS
8
Show member pathways
12.84 PTEN PIK3CA KRAS HRAS CCND1
9 12.83 TP53 TERT RB1 PTEN PIK3CA KRAS
10
Show member pathways
12.8 TP53 PTEN PIK3CA KRAS HRAS EGFR
11
Show member pathways
12.78 TP53 PTEN PIK3CA KRAS HRAS
12
Show member pathways
12.77 TP53 PIK3CA KRAS HRAS CDKN2A
13
Show member pathways
12.74 RB1 KRAS HRAS EGFR CCND1
14
Show member pathways
12.73 TP53 RB1 KRAS HRAS EGFR
15
Show member pathways
12.71 TP53 RB1 PTEN PIK3CA KRAS HRAS
16
Show member pathways
12.7 PIK3CA KRAS HRAS EGFR CCND1
17
Show member pathways
12.69 PTEN PIK3CA KRAS HRAS EGFR CD274
18
Show member pathways
12.69 TP53 TERT RB1 PTEN PIK3CA KRAS
19
Show member pathways
12.68 TP53 PTEN PIK3CA KRAS HRAS EGFR
20
Show member pathways
12.65 TP53 PIK3CA KRAS HRAS EGFR
21
Show member pathways
12.6 TP53 PTEN PIK3CA KRAS HRAS EGFR
22
Show member pathways
12.6 TP53 PTEN PIK3CA KRAS HRAS EGFR
23
Show member pathways
12.56 PTEN PIK3CA KRAS HRAS CCND1
24
Show member pathways
12.52 TP53 PIK3CA KRAS HRAS EGFR
25 12.51 TP53 PTEN PIK3CA MIR223 KRAS HRAS
26
Show member pathways
12.48 TP53 RB1 PTEN CDKN2A CD82 CCND1
27
Show member pathways
12.47 PIK3CA HRAS EGFR CCND1
28
Show member pathways
12.47 TP53 PTEN PIK3CA HRAS CCND1
29
Show member pathways
12.46 PTEN PIK3CA KRAS HRAS
30
Show member pathways
12.46 PIK3CA KRAS HRAS EGFR
31 12.43 TP53 RB1 CDKN2A CCND1
32
Show member pathways
12.41 TP53 RB1 CDKN2A CCND1
33
Show member pathways
12.41 PIK3CA KRAS HRAS EGFR
34
Show member pathways
12.41 TP53 PTEN PIK3CA HRAS EGFR CCND1
35 12.39 TP53 PIK3CA KRAS HRAS EGFR CCND1
36
Show member pathways
12.38 PIK3CA HRAS EGFR CCND1
37 12.38 TP53 RB1 PIK3CA KRAS HRAS CDKN2A
38
Show member pathways
12.36 TP53 KRAS HRAS EGFR
39
Show member pathways
12.35 PIK3CA KRAS HRAS EGFR
40
Show member pathways
12.33 TP53 TERT RB1 KRAS EGFR
41
Show member pathways
12.32 TP53 RB1 PTEN CCND1
42
Show member pathways
12.28 TP53 RB1 PTEN PIK3CA KRAS HRAS
43 12.26 TP53 KRAS EGFR CCND1
44 12.26 PTEN KRAS HRAS EGFR
45
Show member pathways
12.24 TP53 PIK3CA KRAS HRAS
46
Show member pathways
12.24 PTEN PIK3CA KRAS HRAS EGFR
47 12.23 TP53 RB1 PTEN KRAS EGFR CCND1
48
Show member pathways
12.21 TP53 PIK3CA KRAS HRAS
49 12.17 TP53 RB1 PTEN EGFR CD82
50
Show member pathways
12.17 PTEN PIK3CA KRAS HRAS EGFR CCND1

GO Terms for Penile Cancer

Cellular components related to Penile Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.92 TP53 TERT RB1 PTEN

Biological processes related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 PTEN KRAS HRAS HOXA3 EGFR CCND1
2 positive regulation of cell migration GO:0030335 9.9 PDPN HRAS EGFR CD274
3 negative regulation of gene expression GO:0010629 9.89 TP53 TERT RB1 MIR509-1 HRAS
4 positive regulation of protein phosphorylation GO:0001934 9.86 KRAS HRAS EGFR CCND1
5 negative regulation of cell proliferation GO:0008285 9.85 TP53 RB1 PTEN PDPN HRAS CDKN2A
6 regulation of cell cycle GO:0051726 9.84 TP53 RB1 PTEN CCND1
7 negative regulation of neuron apoptotic process GO:0043524 9.81 TERT PIK3CA KRAS HRAS
8 cell cycle arrest GO:0007050 9.76 TP53 RB1 HRAS CDKN2A
9 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.74 RB1 PTEN CDKN2A
10 positive regulation of MAP kinase activity GO:0043406 9.72 KRAS HRAS EGFR
11 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.7 TERT EGFR CCND1
12 negative regulation of mitotic cell cycle GO:0045930 9.65 TP53 RB1 EGFR
13 regulation of protein stability GO:0031647 9.62 TERT PTEN KRAS CDKN2A
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 TP53 EGFR
15 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.59 TP53 TERT
16 mitotic G1 DNA damage checkpoint GO:0031571 9.58 TP53 CCND1
17 response to isolation stress GO:0035900 9.58 KRAS HRAS
18 liver development GO:0001889 9.55 PIK3CA KRAS HRAS EGFR CCND1
19 replicative senescence GO:0090399 9.43 TP53 TERT CDKN2A
20 response to UV-A GO:0070141 9.4 EGFR CCND1
21 Ras protein signal transduction GO:0007265 9.35 TP53 RB1 KRAS HRAS CDKN2A
22 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN MIR509-1 MIR223 KRAS HRAS

Molecular functions related to Penile Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.65 TP53 PTEN EGFR CDKN2A CCND1
2 enzyme binding GO:0019899 9.35 TP53 RB1 PTEN EGFR CCND1
3 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 CDKN2A
4 disordered domain specific binding GO:0097718 8.8 TP53 RB1 CDKN2A

Sources for Penile Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....